ロード中...

Switching from sildenafil to riociguat for the treatment of PAH and inoperable CTEPH: Real-life experiences

Riociguat is a novel soluble guanylate cyclase stimulator that is approved for the treatment of patients with pulmonary arterial hypertension (PAH) and patients with inoperable chronic thromboembolic pulmonary hypertension (CTEPH) or persistent/recurrent CTEPH after pulmonary endarterectomy (PEA). A...

詳細記述

保存先:
書誌詳細
出版年:Respir Med Case Rep
主要な著者: Andersen, Asger, Korsholm, Kasper, Mellemkjær, Søren, Nielsen-Kudsk, Jens Erik
フォーマット: Artigo
言語:Inglês
出版事項: Elsevier 2017
主題:
オンライン・アクセス:https://ncbi.nlm.nih.gov/pmc/articles/PMC5476463/
https://ncbi.nlm.nih.gov/pubmed/28652963
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.rmcr.2017.06.005
タグ: タグ追加
タグなし, このレコードへの初めてのタグを付けませんか!